Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins
Author:
Funder
National Natural Science Foundation of China
Chinese Academy of Sciences
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology
Reference25 articles.
1. Kinase-targeted cancer therapies: progress, challenges and future directions;Bhullar;Mol Canc,2018
2. Kinase mutations in human disease: interpreting genotype-phenotype relationships;Lahiry;Nat Rev Genet,2010
3. Protein kinase signaling networks in cancer;Brognard;Curr Opin Genet Dev,2011
4. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update;Roskoski;Pharmacol Res,2020
5. The resurgence of covalent drugs;Singh;Nat Rev Drug Discov,2011
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology;Clinical Pharmacology & Therapeutics;2024-07-28
2. Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update;Journal of Medicinal Chemistry;2024-05-07
3. Pharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance study;Expert Opinion on Investigational Drugs;2024-01-02
4. Biotransformation research advances – 2022 year in review;Drug Metabolism Reviews;2023-10-02
5. The Importance of Tracking “Missing” Metabolites: How and Why?;Journal of Medicinal Chemistry;2023-09-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3